SCHEMBL16185138

SCHEMBL16185138

CCOc1cc(-c2cccc(F)c2)cc2c(NC)nc(-c3ncccn3)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 4/20 0.48
▸ MAP4K4 O95819 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CHRNA7 P36544 1/20 0.37
▸ KIT P10721 1/20 0.37
▸ FBP1 P09467 1/20 0.37
▸ PDGFRB P09619 1/20 0.37
▸ PDGFRA P16234 1/20 0.37
▸ EGFR P00533 1/20 0.36
▸ IKBKB O14920 1/20 0.36
▸ CHUK O15111 1/20 0.36
▸ DHODH Q02127 2/20 0.36
▸ ABCG2 Q9UNQ0 2/20 0.36
▸ THRB P10828 1/20 0.35
▸ CYP17A1 P05093 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP11B1 P15538 1/20 0.35
▸ CYP11B2 P19099 1/20 0.35
▸ FFAR1 O14842 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16185167 0.91 GRM5 (0.38) GRM5MAPTLMNACHRNA7KIT
SCHEMBL14474192 0.90 CHRNA7 (0.43) GRM5MAPTLMNACHRNA7KIT
SCHEMBL16185134 0.90 FFAR1 (0.47) GRM5MAP4K4LMNAFFAR1
SCHEMBL16185132 0.89 KIT (0.43) GRM5MAP4K4LMNAKITPDGFRB
SCHEMBL16184848 0.88 GRM5 (0.48) GRM5MAP4K4MAPTLMNAABCG2
SCHEMBL16185139 0.87 GRM5 (0.47) GRM5MAP4K4MAPTLMNACHRNA7
SCHEMBL16185140 0.87 GRM5 (0.48) GRM5MAP4K4MAPTLMNACHRNA7
SCHEMBL14474191 0.86 GRM5 (0.44) GRM5MAP4K4MAPTLMNACHRNA7
SCHEMBL16185137 0.86 GRM5 (0.46) GRM5MAP4K4MAPTLMNACHRNA7
SCHEMBL16185136 0.86 GRM5 (0.44) GRM5MAP4K4MAPTLMNACHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB GRM5 37/4885MAP4K4 635/4885MAPT 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback